

ORCA Therapeutics to present FIH Clinical Data with enhanced oncolytic immunotherapeutic ORCA-010 at the Society for Immunotherapy of Cancer

's-Hertogenbosch, the Netherlands, 08 November, 2021.

ORCA Therapeutics B.V., a clinical-stage biopharmaceutical company developing oncolytic immunotherapy to treat cancer will present first in human clinical study results at the Society for Immunotherapy Conference (SITC) held in Washington DC (USA) from November 12 to November 14.

At the SITC ORCA will provide an update on the development of ORCA's enhanced oncolytic immunotherapy platform, our proprietary scalable production platform and the ongoing phase I/II clinical trial. ORCA's lead compound, ORCA-010, is an enhanced oncolytic adenovirus designed for optimal safety and anti-cancer properties. ORCA-010 is designed to work synergistically with standard of care cancer therapies and is currently in clinical trials in Canada in patients with localized prostate cancer who have received no prior treatment.

Safety data from the phase I dose escalation study demonstrated excellent safety at all dose levels, with only grade I and grade II adverse events observed. Virus replication is evident as demonstrated by increased levels of shedding analysis in urine. Interim MRI analysis at 6 months post treatment demonstrated that patients with significantly enlarged prostates observed a reduction of prostate volume post treatment.

Meet our team at the SITC to learn more about ORCA's enhanced oncolytic immunotherapy platform, our proprietary scalable production platform and the ongoing phase I/II clinical trial.

For more information please visit <http://www.orca-therapeutics.nl/>

Please contact

Kees Groen, PhD., CEO
ORCA Therapeutics B.V.
+31 653648230 info@ORCA-therapeutics.com